Ogsiveo (Nirogacestat)

Nirogacestat, the active ingredient in Ogsiveo, is a gamma‑secretase inhibitor presented as an oral tablet for oral administration. It is approved in the European Union for the treatment of desmoid tumors, a rare soft‑tissue fibromatosis, in adult patients. The drug works by modulating the Notch signaling pathway that contributes to abnormal cell proliferation.

GNH USA supplies Ogsiveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nirogacestat is a gamma‑secretase inhibitor used in the management of desmoid tumors, a rare fibromatosis condition. - Desmoid tumor (aggressive fibromatosis): Reduces tumor size and slows disease progression. - Familial adenomatous polyposis‑associated desmoid disease: Decreases lesion growth and improves symptom control. - Post‑surgical desmoid recurrence prevention: Delays recurrence after tumor resection.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Fatigue: generalized tiredness. - Diarrhea: loose stools, sometimes watery. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Severe infections: opportunistic bacterial or fungal infections. - Hepatic enzyme elevation: increased ALT/AST indicating liver stress. - Interstitial lung disease: inflammation of lung tissue. - Cardiac toxicity: arrhythmias or reduced cardiac function. - Neutropenia: low neutrophil count increasing infection risk. - Anaphylactic reactions: severe allergic response requiring immediate care.

Before initiating therapy, clinicians should consider several safety measures. - Liver monitoring: Perform baseline and periodic liver function tests. - Infection vigilance: Assess for active infections and advise patients to report fever. - Cardiac assessment: Evaluate cardiac history and monitor ECG if indicated. - Pregnancy avoidance: Do not use in pregnant or breastfeeding women unless benefits outweigh risks. - Gastrointestinal caution: Use carefully in patients with pre‑existing GI disorders. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Nirogacestat may interact with other medications; awareness of interaction severity is essential. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce drug exposure. - Concurrent QT‑prolonging agents: increase risk of cardiac arrhythmias. - Other gamma‑secretase inhibitors: additive pharmacologic effects. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may increase plasma levels. - Antacids containing aluminum or magnesium: could affect absorption. - Warfarin: potential alteration of INR, requiring closer monitoring.